Doses of hepatitis vaccines for immune-compromised recipients by age
| Vaccine . | Dose of antigen(s) . | Schedule (0 mo = initiation of vaccination) . | ||
|---|---|---|---|---|
| Dose 1 . | Dose 2 . | Dose 3 . | ||
| HAV (Havrix, GlaxoSmithKline) | ||||
| 0-18 y | 760 U (0.5 mL) | 0 mo* | 6 mo† | NA |
| >18 y | 1440 U (1 mL) | |||
| HBV (Engerix, GlaxoSmithKline) | ||||
| <1‡ y | 10 mcg (0.5 mL) | 0 mo* | 2 mo | 6 mo† |
| 1-10‡ y | 10 mcg (0.5 mL) | |||
| 11-19 y | 20 mcg (1 mL) | |||
| ≥20 y | 40 mcg (2 mL§,||) | |||
| HAV/HBV (Twinrix,*,† GlaxoSmithKline) | ||||
| ≥18 y | 1440 U HAV + 40 mcg HBV (2 mL¶) | 0 mo | NA | 6 mo |
| Vaccine . | Dose of antigen(s) . | Schedule (0 mo = initiation of vaccination) . | ||
|---|---|---|---|---|
| Dose 1 . | Dose 2 . | Dose 3 . | ||
| HAV (Havrix, GlaxoSmithKline) | ||||
| 0-18 y | 760 U (0.5 mL) | 0 mo* | 6 mo† | NA |
| >18 y | 1440 U (1 mL) | |||
| HBV (Engerix, GlaxoSmithKline) | ||||
| <1‡ y | 10 mcg (0.5 mL) | 0 mo* | 2 mo | 6 mo† |
| 1-10‡ y | 10 mcg (0.5 mL) | |||
| 11-19 y | 20 mcg (1 mL) | |||
| ≥20 y | 40 mcg (2 mL§,||) | |||
| HAV/HBV (Twinrix,*,† GlaxoSmithKline) | ||||
| ≥18 y | 1440 U HAV + 40 mcg HBV (2 mL¶) | 0 mo | NA | 6 mo |
In adults, dose 1 HAV and HBV may be combined as Twinrix.
In adults, dose 2 HAV and dose 3 HBV may be combined as Twinrix but given at 6 mo after dose 1.
Pediarix (GlaxoSmithKline) can be substituted for age >6 wk and ≤7 y, and it also contains DTaP and IPV.
Two 1.0 mL doses at 1 site.
Recombivax HB (Merck) is an alternative dialysis formulation that provides 40 mcg of HBV antigen in just 1.0 mL allowing smaller injection at 1 site.
Two 1.0 mL doses at 1 site at 0 and 6 mo.